---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Conventional systemic therapies"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Conventional systemic therapies. Topics: Methotrexate: guideline recommendations on use, comparative efficacy, dosage, and folate supplementation; Methotrexate efficacy in randomized trials: PASI 75 versus placebo and adalimumab; Methotrexate oral solution: FDA-approved indication, dosage, boxed warning, and hepatotoxicity in psoriasis; Methotrexate: guideline statements on dose, principal adverse reactions, and myelosuppression; 7 further topics. 11 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/conventional-systemic-therapies"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Conventional systemic therapies

<a id="heading-2.2.2.1.3"></a>

## 2.2.2.1.3 Conventional Systemic Therapies

<a id="topic-2.2.2.1.3-1"></a>

### Methotrexate: guideline recommendations on use, comparative efficacy, dosage, and folate supplementation

> “Methotrexate is recommended for the treatment of moderate to severe psoriasis in adults.”
> “Methotrexate is less effective than adalimumab and infliximab for cutaneous psoriasis.”
> “Recommended methotrexate dosage typically ranges from 7.5 to 25 mg weekly. The dose can be given as a single dose or in 3 doses over 24 hours.”
> “Administration of folic acid or folinic acid is recommended to reduce the incidence of GI and hepatic adverse effects. Large folic acid and folinic acid doses may reduce the efficacy of methotrexate.”

Source: [Menter et al. (2020)](https://www.jaad.org/article/S0190-9622%2820%2930284-X/fulltext)

<a id="topic-2.2.2.1.3-2"></a>

### Methotrexate efficacy in randomized trials: PASI 75 versus placebo and adalimumab

> “In a randomized controlled trial with 120 patients with psoriasis receiving subcutaneous methotrexate weekly (n = 91) or placebo (n = 29), a PASI 75 score was achieved in 41% (n = 37) of the subcutaneous methotrexate group compared with 10% of the placebo group (relative risk, 3.93; 95% confidence interval [CI], 1.31-11.81; P = .0026)”
> “Methotrexate group performed significantly better than placebo (35.5% of patients achieved PASI 75 compared with 18.9%) but was less effective than adalimumab (79.6% with PASI 75).”

Source: [Menter et al. (2020)](https://www.jaad.org/article/S0190-9622%2820%2930284-X/fulltext)

<a id="topic-2.2.2.1.3-3"></a>

### Methotrexate oral solution: FDA-approved indication, dosage, boxed warning, and hepatotoxicity in psoriasis

> “JYLAMVO is indicated for the treatment of adults with severe psoriasis.”
> “The recommended dosage of JYLAMVO is 10 mg to 25 mg orally once weekly until an adequate response is achieved.”
> “Serious adverse reactions, including death, have been reported with methotrexate.”
> “In patients with psoriasis, fibrosis or cirrhosis may occur in the absence of symptoms or abnormal liver tests; the risk of hepatotoxicity appears to increase with total cumulative dose and generally occurs after receipt of a total cumulative dose of 1.5 g or more.”

Source: [Shorla Oncology JYLAMVO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212479s009lbl.pdf)

<a id="topic-2.2.2.1.3-4"></a>

### Methotrexate: guideline statements on dose, principal adverse reactions, and myelosuppression

> “The recommended initial and maintenance dose is usually 15 mg MTX once weekly.”
> “The most important adverse drug reactions (ADRs) in association with MTX therapy are mucositis, MTX‐induced pneumonitis, hepatotoxicity, and myelosuppression.”
> “Another rare, but serious adverse event of MTX therapy is myelosuppression with an estimated prevalence of <1% (7/100,000 patient years).”

Source: [Nast et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12800871/)

<a id="topic-2.2.2.1.3-5"></a>

### Cyclosporine: guideline recommendations and PASI response rates

> “Cyclosporine is recommended for patients with severe, recalcitrant psoriasis.”
> “Cyclosporine can be recommended as short-term interventional therapy in patients who flare up while on a pre-existing systemic therapy.”
> “At a dose of 3 mg/kg/d, 50% to 70% of patients with psoriasis achieved PASI 75 and 30% to 50% achieved PASI 90”

Source: [Menter et al. (2020)](https://www.jaad.org/article/S0190-9622%2820%2930284-X/fulltext)

<a id="topic-2.2.2.1.3-6"></a>

### Cyclosporine: FDA-approved indication, dosage, and boxed warning for psoriasis

> “Neoral is indicated for the treatment of adult, nonimmunocompromised patients with severe (i.e., extensive and/or disabling), recalcitrant, plaque psoriasis who have failed to respond to at least one”
> “systemic therapy (e.g., PUVA, retinoids, or methotrexate) or in patients for whom other systemic therapies are contraindicated, or cannot be tolerated.”
> “The initial dose of Neoral should be 2.5 mg/kg/day.”
> “Based on patient response, dose increases of approximately 0.5 mg/kg/day should be made to a maximum of 4.0 mg/kg/day.”
> “Psoriasis patients previously treated with PUVA and to a lesser extent, methotrexate or other immunosuppressive agents, UVB, coal tar, or radiation therapy, are at an increased risk of developing skin malignancies when taking Neoral.”
> “Cyclosporine, the active ingredient in Neoral, in recommended dosages, can cause systemic hypertension and nephrotoxicity.”

Source: [Novartis NEORAL prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/050715s041,050716s041,050735s003,050736s001,050737s003,050738s001lbl.pdf)

<a id="topic-2.2.2.1.3-7"></a>

### Cyclosporine nephropathy and malignancies in psoriasis

> “Kidney biopsies from 86 psoriasis patients treated for a mean duration of 23 months with 1.2 to 7.6 mg/kg/day of cyclosporine showed evidence of cyclosporine nephropathy in 18/86 (21%) of the patients.”
> “Tumors were reported in 32 (2.2%) of 1439 psoriasis patients treated with cyclosporine worldwide from clinical trials.”

Source: [Novartis NEORAL prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/050715s041,050716s041,050735s003,050736s001,050737s003,050738s001lbl.pdf)

<a id="topic-2.2.2.1.3-8"></a>

### Acitretin: guideline recommendation and PASI 75 response

> “Acitretin can be recommended as monotherapy for plaque psoriasis.”
> “In one study, 23% of patients treated with acitretin 50 mg/d achieved PASI 75 after 8 weeks of therapy, with some patients experiencing complete clearance of skin disease”

Source: [Menter et al. (2020)](https://www.jaad.org/article/S0190-9622%2820%2930284-X/fulltext)

<a id="topic-2.2.2.1.3-9"></a>

### Acitretin: FDA-approved indication, dosage, and pregnancy warning

> “SORIATANE is indicated for the treatment of severe psoriasis in adults.”
> “Therapy with SORIATANE should be initiated at 25 to 50 mg per day, given as a single dose with the main meal.”
> “SORIATANE must not be used by females who are pregnant, or who intend to become pregnant during therapy or at any time for at least 3 years following discontinuation of therapy.”

Source: [Stiefel SORIATANE prescribing information (2023)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/019821s029lbl.pdf)

<a id="topic-2.2.2.1.3-10"></a>

### Network meta-analysis: methotrexate and ciclosporin compared with biologics, apremilast, and placebo

> “Infliximab, adalimumab, ixekizumab, and risankizumab were more effective than methotrexate (infliximab: RR 2.86, 95% CI 2.15 to 3.80; adalimumab: RR 3.73, 95% CI 2.25 to 6.19; ixekizumab: RR 2.05, 95% CI 1.43 to 2.94; risankizumab: RR 2.37, 95% CI 1.59 to 3.54).”
> “Ciclosporin and methotrexate were superior to apremilast for reaching PASI 90.”
> “There was evidence of a lower risk of SAEs for participants on methotrexate compared to placebo (RR 0.15, 95% CI 0.03 to 0.72).”
> “Our confidence in the results for non‐targeted systemic treatments is limited due to concerns regarding study conduct.”

Source: [Sbidian et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12327466/)

<a id="topic-2.2.2.1.3-11"></a>

### Systemic nonbiologic therapy guideline scope and development under American Academy of Dermatology regulations in collaboration with the National Psoriasis Foundation

> “This guideline will cover the use of oral-systemic, nonbiologic medication in the treatment of psoriasis.”
> “This guideline has been developed in accordance with the American Academy of Dermatology (AAD)/AAD Association Administrative Regulations for Evidence-based Clinical Practice Guidelines (May 2014)”
> “Additionally, this guideline is developed in collaboration with the National Psoriasis Foundation, and as part of the review process; the National Psoriasis Foundation medical board members provided their feedback.”

Source: [Menter et al. (2020)](https://www.jaad.org/article/S0190-9622%2820%2930284-X/fulltext)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
